Drug Safety

Intelligent Risk Communication: Can it be Improved?
pp. 1-6(6)
Author: Czarnecki, Andrzej

Benefits and Risks of Antipsychotic Polypharmacy: An Evidence-Based Review of the Literature
pp. 7-20(14)
Authors: Tranulis, Constantin; Skalli, Leila; Lalonde, Pierre; Nicole, Luc; Stip, Emmanuel

Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review
pp. 21-37(17)
Authors: Agbabiaka, Taofikat B.; Savović, Jelena; Ernst, Edzard

Data Resources for Investigating Drug Exposure during Pregnancy and Associated Outcomes: The General Practice Research Database (GPRD) as an Alternative to Pregnancy Registries
pp. 39-51(13)
Authors: Charlton, Rachel A.; Cunnington, Marianne C.; de Vries, Corinne S.; Weil, John G.

Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
pp. 53-65(13)
Authors: Filippatos, Theodosios D.; Derdemezis, Christos S.; Gazi, Irene F.; Nakou, Eleni S.; Mikhailidis, Dimitri P.; Elisaf, Moses S.

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation
pp. 67-77(11)
Authors: Kubitza, Dagmar; Mueck, Wolfgang; Becka, Michael

Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson's Disease Dementia: A Retrospective Analysis of a Double-Blind Trial and an Open-Label Extension
pp. 79-94(16)
Authors: Oertel, Wolfgang; Poewe, Werner; Wolters, Erik; Peter Paul De Deyn,; Emre, Murat; Kirsch, Courtney; Hsu, Chuanchieh; Tekin, Sibel; Lane, Roger